About Aquila Path
Built from pathology. Focused on the decisions that follow.
Built by physicians and grounded in more than a decade of pathology experience, Aquila Path is developing outcome-linked tissue intelligence for more informed prostate cancer decisions.
Clearer biological context for the decisions that follow
Routine pathology reveals cancer. Understanding how the disease may behave is more complex. Aquila Path was created to connect patterns within routine prostate tissue to longitudinal outcomes, helping clinicians develop a more informed view of biological risk.
Our goal is not to replace established pathology or physician judgment. It is to provide greater biological context for the conversations, evaluations, and care decisions that follow.
Purpose
To bring greater clarity, evidence, and confidence to precision oncology decisions.
Mission
To transform the rich information in routine pathology into clinically meaningful tissue intelligence.
A Physician-Led Beginning
The question began in clinical practice
Aquila Path began with a question encountered in prostate cancer care: how could the biological information already present in routine tissue be interpreted with greater consistency, context, and clinical relevance?
That question shaped the company from the beginning. Practicing pathologists, urologists, and oncology experts continue to guide how the technology is developed, validated, reported, and considered in practice.
Real clinical questions
Development begins with the decisions physicians and patients face.
Physician-led development
Clinical relevance shapes the technology, evidence strategy, and reporting experience.
Judgment remains central
TruGrade™ is designed to complement conventional pathology and physician-led evaluation.
Our Origin
A decade of pathology heritage
Aquila Path was established within the PathNet laboratory ecosystem, drawing on more than a decade of experience in specialty pathology, digital whole-slide imaging, laboratory operations, and collaboration with independent urology practices.
PathNet provides the clinical expertise and infrastructure. Aquila Path builds on that foundation to develop AI-enabled diagnostic and prognostic technologies using pathology images and de-identified longitudinal outcomes. Together, this connection keeps the technology grounded in real laboratory workflows, clinical decisions, and the needs of physicians in practice.
Platform and Ecosystem
Positioned to deliver
One connected ecosystem from clinical question to clinical adoption.
Clinical Practice
Real clinical questions
PathNet
Connected pathology ecosystem
Longitudinal Outcomes
Outcome-linked evidence
AI Platform
Tissue intelligence
Clinical Validation
Evidence generation
Commercial Deployment
Operational translation
Clinical Adoption
Physician-led use
One integrated ecosystem designed to translate AI into clinical practice.
Leadership
Clinical depth with technology and execution experience
Jason Camilletti
Chief Executive Officer
Jason Heard
President
Adam Cole, MD
Chief Medical Officer
Jayendra Shinde, PhD
Chief Technology and AI Officer
Matt Dowell
Chief Financial Officer
SCIENTIFIC AND CLINICAL ADVISORS
Expertise around the clinical questions that matter
Aquila Path’s advisory focus brings specialist perspective to the clinical, scientific, and operational questions that shape responsible development.
Genitourinary Pathology
Diagnostic interpretation and validation design.
Urologic Oncology
Clinical relevance and patient context.
Digital Pathology
Laboratory Workflow And Implementation.
Clinical Development
Evidence strategy and clinically relevant endpoints.